Furagin, tablets 50 mg 30 pcs

Furagin is an antibacterial drug, a nitrofuran derivative. It acts bacteriostatically. The mechanism of action of Furagin is related to the effect on the enzymes involved in the transfer of hydrogen in the cells of sensitive microorganisms. High bacteriostatic activity of Furagin is due to the presence of aromatic nitro group.

The drug is active against Gram-positive bacteria: Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus faecalis; against Gram-negative bacteria: Enterobacteriaceae, Escherichia coli, Klebsiella pneumoniae.
Pseudomonas aeruginosa is resistant to the drug.

The minimum bacteriostatic concentration of Furagin (1 µg/ml) is 10-20 times lower than that of other nitrofuran derivatives. Furagin has the most pronounced effect in acidic environment (pH 5.5), alkaline environment prevents the action of the drug.

Indications

Treatment of infectious and inflammatory diseases of the urinary tract, prevention of infectious complications after surgical interventions on the genitourinary system.

Pharmacological effect

Pharmacotherapeutic group
antimicrobial agent, nitrofuran

ATX code
D08AF

Pharmacodynamics:
Effective against gram-positive cocci (Staphylococcus spp., Streptococcus spp.), gram-negative rods (Escherichia coli, Salmonella spp., Shigella spp., Klebsiella spp.). Plasmodium aeruginosa, Enterococcus spp., Acinetobacter spp., most strains of Proteus spp., Serratia spp. are resistant. The mechanism of action is associated with inhibition of nucleic acid synthesis. Depending on the concentration, it has a bactericidal or bacteriostatic effect.

Against most bacteria, the bacteriostatic concentration is 10-20 μg/ml. The bactericidal concentration is approximately 2 times higher. Under the influence of nitrofurans in microorganisms, the activity of the respiratory chain and the tricarboxylic acid cycle (Krebs cycle) is suppressed, as well as other biochemical processes are inhibited, which leads to the destruction of their shell or cytoplasmic membrane. As a result of the action of nitrofurans, microorganisms produce fewer toxins, and therefore an improvement in the general condition of the patient is possible even before a pronounced suppression of the growth of microflora.

Nitrofurans, unlike many other antimicrobial drugs, not only do not suppress the body’s immune system, but, on the contrary, activate it (increase the complement titer and the ability of leukocytes to phagocytose microorganisms.

Pharmacokinetics:
Absorption – in the small intestine by passive diffusion. Absorption of nitrofurans from the distal segment of the small intestine exceeds absorption from the proximal and medial segments by 2 and 4 times, respectively. Poorly absorbed in the colon.

Distributed evenly. Contains in high concentrations in lymph; in bile its concentration is several times higher than in serum, in cerebrospinal fluid – several times lower than in serum; saliva contains up to 30% of its concentration in serum; the concentration in the blood and tissues is small, which is associated with its rapid excretion, while its concentration in the urine is much higher than in the blood. The maximum concentration in the blood serum lasts from 3 to 7-8 hours, in the urine it is detected after 3-4 hours. It does not change the pH of the urine, unlike nitrofurantoin. Metabolized in the liver (less than 10%), with a decrease in the excretory function of the kidneys, the intensity of metabolism increases.

It is excreted by the kidneys by glomerular filtration and tubular secretion (85%), partially subjected to reverse reabsorption in the tubules. At low concentrations in urine, the process of filtration and secretion predominates; at high concentrations, secretion decreases and reabsorption increases. Being a weak acid, it does not dissociate; at acidic urine pH values, it undergoes intense reabsorption, which can increase systemic side effects.

Special instructions

Drink plenty of fluids to prevent side effects.

To prevent the development of neuritis, it is necessary to prescribe B vitamins.

During the treatment period, you should refrain from activities that require increased concentration and speed of psychomotor reactions.

Furagin turns urine brown.

Active ingredient

Furazidin

Composition

composition per tablet:

active ingredient – furagin (furazidin) 50.0 mg;

excipients – lactose monohydrate 18.80 mg, modified corn starch 20.00 mg, sucrose 10.00 mg, polysorbate 80 (Tween 80) 0.20 mg, stearic acid 1.00 mg.

Contraindications

hypersensitivity to nitrofuran derivatives
renal dysfunction
liver dysfunction
pregnancy and lactation
children under 18 years of age (for this dosage form)
sucrase/isomaltase/lactase deficiency
fructose/lactose intolerance
glucose-galactose malabsorption

Furagin is not recommended for use in cases of urosepsis and infections of the kidney parenchyma.

With caution:
do not use for anemia, lung diseases (especially in patients over 65 years of age), diseases of the nervous system, diabetes mellitus, deficiency of glucose-6-phosphate dehydrogenase, B vitamins and folic acid.

Side Effects

Blood and lymphatic system disorders
agranulocytosis, thrombocytopenia, aplastic anemia
Immune system disorders
pruritus, papular rash, angioedema, urticaria, exfoliative dermatitis, erythema multiforme
Nervous system disorders
dizziness, headache, drowsiness, peripheral neuropathy
Visual disorders
visual impairment
Vascular disorders
intracranial hypertension
Disorders of the respiratory system, chest and mediastinal organs
acute or chronic reaction from the lungs. An acute reaction from the lungs develops quickly and manifests itself in the form of acute shortness of breath, fever, chest pain, cough with or without sputum, eosinophilia (reversible after discontinuation of the drug). Skin rash, itching, urticaria, angioedema and myalgia have also been reported. Chronic pulmonary reaction may occur over a long period of time after stopping treatment and is characterized by a gradual increase in dyspnea, increased respiratory rate, intermittent fever, eosinophilia, progressive cough, and interstitial pneumonitis and/or pulmonary fibrosis.
Gastrointestinal disorders
nausea, vomiting, loss of appetite, diarrhea, pancreatitis
Disorders of the liver and biliary tract
cholestatic jaundice, hepatitis
Musculoskeletal and connective tissue disorders
arthralgia
General disorders and disorders at the injection site
frequency unknown: fever, weakness, reversible alopecia, dark yellow or brown urine.

Interaction

Ristomycin, chloramphenicol, sulfonamides – risk of hematotoxicity. The simultaneous use of other nitrofuran derivatives, as well as drugs that “acidify” the urine (including ascorbic acid, calcium chloride) should be avoided.

Ethanol may increase side effects.

Overdose

Symptoms: neurotoxic reactions, polyneuritis, liver dysfunction, acute toxic hepatitis.

Treatment: withdrawal of the drug, taking large amounts of fluid, symptomatic therapy, antihistamines, B vitamins. There is no specific antidote.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 30 °C

Shelf life

5 years

Manufacturer

Olainfarm, Latvia